- About this Journal
- Abstracting and Indexing
- Aims and Scope
- Article Processing Charges
- Articles in Press
- Author Guidelines
- Bibliographic Information
- Citations to this Journal
- Contact Information
- Editorial Board
- Editorial Workflow
- Free eTOC Alerts
- Publication Ethics
- Reviewers Acknowledgment
- Submit a Manuscript
- Subscription Information
- Table of Contents
Journal of Oncology
Volume 2012 (2012), Article ID 601682, 8 pages
Cucurbitacin B Causes Increased Radiation Sensitivity of Human Breast Cancer Cells via G2/M Cell Cycle Arrest
1Faculty of Medical Technology, Mahidol University, Bangkok, Thailand
2Free Radical and Radiation Biology Program, Department of Radiation Oncology, University of Iowa, Iowa City, IA 52242, USA
3Faculty of Science, Ramkhamhaeng University, Bangkok, Thailand
Received 23 January 2012; Accepted 27 March 2012
Academic Editor: Julian J. Raffoul
Copyright © 2012 Suwit Duangmano et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- J. Ferlay, H. R. Shin, F. Bray, D. Forman, C. Mathers, and D. M. Parkin, “Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008,” International Journal of Cancer, vol. 127, no. 12, pp. 2893–2917, 2010.
- A. Jemal, R. Siegel, J. Xu, and E. Ward, “Cancer statistics, 2010,” CA Cancer Journal for Clinicians, vol. 60, no. 5, pp. 277–300, 2010.
- A. Kols, “Breast cancer: increasing incidence, Limited Options,” Out Look, vol. 19, no. 4, pp. 1–8, 2002.
- G. Konecny, G. Pauletti, M. Pegram et al., “Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer,” Journal of the National Cancer Institute, vol. 95, no. 2, pp. 142–153, 2003.
- K. R. Bauer, M. Brown, R. D. Cress, C. A. Parise, and V. Caggiano, “Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California Cancer Registry,” Cancer, vol. 109, no. 9, pp. 1721–1728, 2007.
- M. J. Kim, J. Y. Ro, S. H. Ahn, H. H. Kim, S. B. Kim, and G. Gong, “Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes,” Human Pathology, vol. 37, no. 9, pp. 1217–1226, 2006.
- C. Wiwat and W. Silapa-archa, “The antimicrobial activities of Cucurbitaceous plants,” Mahidol University Journal of Pharmaceutical Sciences, vol. 11, pp. 12–18, 1984.
- B. Jayaprakasam, N. P. Seeram, and M. G. Nair, “Anticancer and antiinflammatory activities of cucurbitacins from Cucurbita andreana,” Cancer Letters, vol. 189, no. 1, pp. 11–16, 2003.
- N. Wakimoto, D. Yin, J. O'Kelly et al., “Cucurbitacin B has a potent antiproliferative effect on breast cancer cells in vitro and in vivo,” Cancer Science, vol. 99, no. 9, pp. 1793–1797, 2008.
- T. Liu, H. Peng, M. Zhang, Y. Deng, and Z. Wu, “Cucurbitacin B, a small molecule inhibitor of the Stat3 signaling pathway, enhances the chemosensitivity of laryngeal squamous cell carcinoma cells to cisplatin,” European Journal of Pharmacology, vol. 641, no. 1, pp. 15–22, 2010.
- G. B. Iwanski, D. H. Lee, S. En-Gal et al., “Cucurbitacin B, a novel in vivo potentiator of gemcitabine with low toxicity in the treatment of pancreatic cancer,” British Journal of Pharmacology, vol. 160, no. 4, pp. 998–1007, 2010.
- K. T. Chan, F. Y. Meng, Q. Li et al., “Cucurbitacin B induces apoptosis and S phase cell cycle arrest in BEL-7402 human hepatocellular carcinoma cells and is effective via oral administration,” Cancer Letters, vol. 294, no. 1, pp. 118–124, 2010.
- D. H. Lee, N. H. Thoennissen, C. Goff et al., “Synergistic effect of low-dose cucurbitacin B and low-dose methotrexate for treatment of human osteosarcoma,” Cancer Letters, vol. 306, no. 2, pp. 161–170, 2011.
- T. Haritunians, S. Gueller, L. Zhang et al., “Cucurbitacin B induces differentiation, cell cycle arrest, and actin cytoskeletal alterations in myeloid leukemia cells,” Leukemia Research, vol. 32, no. 9, pp. 1366–1373, 2008.
- S. Duangmano, S. Dakeng, W. Jiratchariyakul, A. Suksamrarn, D. R. Smith, and P. Patmasiriwat, “Antiproliferative effects of cucurbitacin B in breast cancer cells: down-regulation of the c-Myc/hTERT/telomerase pathway and obstruction of the cell cycle,” International Journal of Molecular Sciences, vol. 11, no. 12, pp. 5323–5338, 2010.
- T. M. Pawlik and K. Keyomarsi, “Role of cell cycle in mediating sensitivity to radiotherapy,” International Journal of Radiation Oncology *Biology* Physics, vol. 59, no. 4, pp. 928–942, 2004.
- T. Terasima and L. J. Tolmach, “X-ray sensitivity and DNA synthesis in synchronous populations of HeLa cells,” Science, vol. 140, no. 3566, pp. 490–492, 1963.
- W. K. Sinclair and R. A. Morton, “X-ray sensitivity during the cell generation cycle of cultured Chinese hamster cells,” Radiation Research, vol. 29, no. 3, pp. 450–474, 1966.
- C. X. Geng, Z. C. Zheng, J. Y. Wang, S. Y. Xuan, and C. M. Lin, “Docetaxel shows radiosensitization in human hepatocellular carcinoma cells,” World Journal of Gastroenterology, vol. 11, no. 19, pp. 2990–2993, 2005.
- J. C. Chen, M. H. Chiu, R. L. Nie, G. A. Cordel, and S. X. Qiuz, “Cucurbitacins and cucurbitane glycosides: structures and biological activities,” Natural Product Reports, vol. 22, no. 3, pp. 386–399, 2005.
- M. R. Farias, E. P. Schenkel, R. Mayer, and G. Rucker, “Cucurbitacins as constituents of Wilbrandia ebracteata,” Planta Medica, vol. 59, no. 3, pp. 272–275, 1993.
- S. Kongtun, W. Jiratchariyakul, T. Kummalue, P. Tan-ariya, S. Kunnachak, and A. W. Frahm, “Cytotoxic properties of root extract and fruit juice of Trichosanthes cucumerina,” Planta Medica, vol. 75, no. 8, pp. 839–842, 2009.
- S. Dakeng, S. Duangmano, W. Jiratchariyakul, Y. U-Pratya, O. Bögler, and P. Patmasiriwat, “Inhibition of Wnt signaling by cucurbitacin B in breast cancer cells: reduction of Wnt associated proteins and reduced translocation of galectin-3-mediated β-catenin to the nucleus,” Journal of Cellular Biochemistry, vol. 113, no. 1, pp. 49–60, 2012.
- O. Pradier, M. Rave-Fränk, H. Schmidberger et al., “Effects of paclitaxel in combination with radiation on human head and neck cancer cells (ZMK-1), cervical squamous cell carcinoma (CaSki), and breast adenocarcinoma cells (MCF-7),” Journal of Cancer Research and Clinical Oncology, vol. 125, no. 1, pp. 20–27, 1999.
- C. E. Leonard, D. C. Chan, T. C. Chou, R. Kumar, and P. A. Bunn, “Paclitaxel enhances in vitro radiosensitivity of squamous carcinoma cell lines of the head and neck,” Cancer Research, vol. 56, no. 22, pp. 5198–5204, 1996.
- M. S. Sheikh, Y. Q. Chen, M. L. Smith, and A. J. Fornace, “Role of p21(Waf1/Cip1/Sdi1) in cell death and DNA repair as studied using a tetracycline-inducible system in p53-deficient cells,” Oncogene, vol. 14, no. 15, pp. 1875–1882, 1997.